Abstract PD4-01: Response according to revised RANO criteria is associated with overall survival in breast cancer patients with leptomeningeal metastasis
Gaia Griguolo(University of North Carolina at Chapel Hill), Valentina Guarneri(Istituto Oncologico Veneto), Francesca Caumo(Istituto Oncologico Veneto), Stéphane Pouderoux(Institut de Recherche en Cancérologie de Montpellier), Amélie Darlix(Institut de Recherche en Cancérologie de Montpellier), William Jacot(Inserm), Michele Bottosso(University of Padua), Maria Vittoria Dieci(Istituto Oncologico Veneto), Vittoria Aldegheri(Istituto Oncologico Veneto), Federica Miglietta(University of Padua)
Cited by 0
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
|Annals of Oncology|2023|298